Mather Group
KYMR icon

Mather Group’s Kymera Therapeutics KYMR Stock Holding History

Mather Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$22.4K Buy
+200
New +$22.9K ﹤0.01% 1404

Other funds holding KYMR

KMWM
Keudell/Morrison Wealth Management Salem, Oregon $562M AUM 21.01% 1-Year Est. Return
NAM
NorthCrest Asset Manangement Plymouth, Minnesota $4.24B AUM 32.82% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
CIA
Cape Investment Advisory Mcdonough, Georgia $388M AUM 17.15% 1-Year Est. Return

Mather Group's KYMR Position: Q3 2026 in Review

Mather Group opened a new position in Kymera Therapeutics (KYMR) in Q3 2026: 200 shares worth $22.4K. The stake represents ﹤0.01% of the portfolio and ranks #1404 among its holdings.

14 funds tracked by Wall St. Rank hold KYMR as of Q3 2026.

  • Mather Group held 200 shares of Kymera Therapeutics worth $22.4K as of Q3 2026.
  • Kymera Therapeutics was a new Mather Group position in Q3 2026.
  • Kymera Therapeutics made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #1404 holding.
  • 14 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.